For the quarter ending 2025-12-31, BNTC had $94,311K increase in cash & cash equivalents over the period. -$3,787K in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Unrealized loss on investment | - | - | 0 |
| Net loss | -11,837 | -8,965 | -37,917 |
| Depreciation and amortization | 14 | 13 | 66 |
| Amortization of right-of-use assets | 106 | 105 | 330 |
| Gain on extinguishment of liabilities | 0 | - | 764 |
| Share-based compensation expense | 7,379 | 5,180 | 17,426 |
| Trade and other receivables | -123 | -30 | -197 |
| Prepaid and other assets | 195 | -156 | 111 |
| Trade and other payables | 701 | 125 | -2,378 |
| Accrued employee benefits | 19 | 37 | -81 |
| Lease liabilities | -86 | -32 | -356 |
| Net cash used in operating activities | -3,776 | -3,351 | -23,588 |
| Purchase of property and equipment | 11 | - | 18 |
| Net cash used in investing activities | -11 | 0 | -18 |
| Proceeds from issuance of common stock, pre-funded warrants, and common warrants | - | - | 30,460 |
| Proceeds from the issuance of common stock | 104,495 | - | - |
| Proceeds from exercise of pre-funded warrants, series 2 warrants and common warrants | 0 | 0 | 42,344 |
| Share issuance transaction costs | 6,265 | - | 2,319 |
| Net cash provided by financing activities | 98,230 | 0 | 70,485 |
| Effects of exchange rate changes on cash, cash equivalents, and restricted cash | -132 | 86 | 49 |
| Net increase in cash, cash equivalents, and restricted cash | 94,311 | -3,265 | 46,928 |
| Cash and cash equivalents at beginning of period | 94,592 | 97,857 | 50,929 |
| Cash and cash equivalents at end of period | 188,903 | 94,592 | 97,857 |
Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc. (BNTC)